355 results on '"Cosio, Borja G."'
Search Results
2. International Variation in Severe Exacerbation Rates in Patients With Severe Asthma
3. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma
4. Lung-function trajectories: relevance and implementation in clinical practice
5. Heteroatom-tagged proteomics of lung cancer and chronic obstructive pulmonary disease human serum reveal alterations in selenoproteins
6. Exploring Definitions and Predictors of Response to Biologics for Severe Asthma
7. Association between occupational exposure and chronic obstructive pulmonary disease and respiratory symptoms in the Spanish population
8. Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry
9. Impact of Applying the Global Lung Initiative Criteria for Airway Obstruction in GOLD Defined COPD Cohorts: The BODE and CHAIN Experience
10. Tobacco Patterns and Risk of Chronic Obstructive Pulmonary Disease: Results From a Cross-Sectional Study
11. Redefining the Role of Bronchoscopy in the Workup of Severe Uncontrolled Asthma in the Era of Biologics: A Prospective Study
12. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry
13. Validation of a Pathological Score for the Assessment of Bronchial Biopsies in Severe Uncontrolled Asthma: Beyond Blood Eosinophils
14. Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy
15. Immunosensors made of polymer-infused porous paper for the non-invasive detection of airways cytokines trapped by porous face masks
16. Trends of COPD in Spain: Changes Between Cross Sectional Surveys 1997, 2007 and 2017
17. Dissociation between physical capacity and daily physical activity in COPD patients. A population-based approach
18. AERIFY-1/-2: 2 phase 3 randomised controlled trials of itepekimab in former smokers with moderate-to-severe COPD
19. Lung-function trajectories: relevance and implementation in clinical practice
20. Is Inhaler Technique Adequately Assessed and Reported in Clinical Trials of Asthma and Chronic Obstructive Pulmonary Disease Therapy? A Systematic Review and Suggested Best Practice Checklist
21. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma
22. [Translated article] Spanish COPD Guideline (GesEPOC) Update: Comorbidities, Self-Management and Palliative Care
23. [Translated article] Spanish COPD Guidelines (GesEPOC 2021): Non-pharmacological Treatment Update
24. Actualización de la Guía Española de la EPOC (GesEPOC): comorbilidades, automanejo y cuidados paliativos
25. Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento no farmacológico
26. [Translated article] Spanish COPD Guidelines (GesEPOC) 2021 Update. Diagnosis and Treatment of COPD Exacerbation Syndrome
27. Actualización 2021 de la guía española de la EPOC (GesEPOC). Diagnóstico y tratamiento del síndrome de agudización de la EPOC
28. [Translated article] Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD
29. Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable
30. Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years
31. Reply to “Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry”
32. Biologics in COPD
33. Implementation of an Integrated Care Model for Frequent-Exacerbator COPD Patients: A Controlled Prospective Study
34. Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score
35. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial
36. Telerehabilitation Programme as a Maintenance Strategy for COPD Patients: A 12-Month Randomized Clinical Trial
37. Prevalence and Determinants of COPD in Spain: EPISCAN II
38. Eosinophilic COPD Patients Display a Distinctive Serum miRNA Profile From Asthma and Non-eosinophilic COPD
39. International Severe Asthma Registry: Mission Statement
40. Determinants and Differences in Satisfaction with the Inhaler Among Patients with Asthma or COPD
41. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma
42. Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma
43. Asthma—COPD Overlap
44. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study
45. Determinants of the Appearance and Progression of Early-Onset Chronic Obstructive Pulmonary Disease in Young Adults. A Case–Control Study With Follow-Up
46. EARLY COPD: determinantes de la aparición y progresión de la enfermedad pulmonar obstructiva crónica en adultos jóvenes. Protocolo de un estudio caso-control con seguimiento
47. Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study
48. The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease
49. Proyecto de biomarcadores y perfiles clínicos personalizados en la enfermedad pulmonar obstructiva crónica (proyecto BIOMEPOC)
50. 10 Years After EPISCAN: A New Study on the Prevalence of COPD in Spain—A Summary of the EPISCAN II Protocol
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.